Success Metrics

Clinical Success Rate

88.4%

Based on 61 completed trials

Completion Rate

88%(61/69)

Active Trials

6(6%)

Results Posted

85%(52 trials)

Terminated

8(8%)

Phase Distribution

Ph early_phase_1

Ph phase_1

Ph phase_4

24%

Ph phase_3

35%

Ph phase_2

21%

Ph not_applicable

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution87 total trials

Early Phase 1First-in-human

3(3.4%)

Phase 1Safety & dosage

5(5.7%)

Phase 2Efficacy & side effects

20(23.0%)

Phase 3Large-scale testing

34(39.1%)

Phase 4Post-market surveillance

23(26.4%)

N/ANon-phased studies

2(2.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

84.7%

61 of 72 finished

Non-Completion Rate

15.3%

11 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(7)

Completed(61)

Terminated(11)

Other(18)

Detailed Status

Completed61

unknown18

Terminated8

Recruiting4

Withdrawn3

Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

88.4%

Most Advanced

Phase 4

Trials by Phase

Early Phase 13 (3.4%)

Phase 15 (5.7%)

Phase 220 (23.0%)

Phase 334 (39.1%)

Phase 423 (26.4%)

N/A2 (2.3%)

Trials by Status

terminated88%

unknown1819%

withdrawn33%

recruiting44%

active_not_recruiting22%

completed6163%

not_yet_recruiting11%

Recent Activity

6 active trials

Showing 5 of 97

terminatedphase_2

A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC

NCT05144529

completedphase_2

Evolocumab in Acute Coronary Syndrome

NCT03515304

completedphase_4

The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascular Disease

NCT03829046

active_not_recruitingphase_2

A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)

NCT06284564

not_yet_recruitingearly_phase_1

Mechanistic Clinical Trial of PCSK9 Inhibition for AAA

NCT06081153

View all 97 trials

Clinical Trials (97)

Showing 20 of 97 trialsScroll for more

NCT05144529Phase 2

A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC

Terminated

NCT03515304Phase 2

Evolocumab in Acute Coronary Syndrome

Completed

NCT03829046Phase 4

The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascular Disease

Completed

NCT06284564Phase 2

A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)

Active Not Recruiting

NCT06081153Early Phase 1

Mechanistic Clinical Trial of PCSK9 Inhibition for AAA

Not Yet Recruiting

NCT04608474Phase 4

Lipid Management in Renal Transplant Recipients Using Evolocumab.

Completed

NCT06700720Phase 2

YN001-004 in Patients With Coronary Atherosclerosis in Australia

Recruiting

NCT06740552

Evolocumab in Patients With Multivessel Coronary Disease After Acute Myocardial Infarction: A Target Trial Emulation

Completed

NCT03337698Phase 1

A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)

Completed

NCT03872401Phase 3

Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

Completed

NCT05152888Phase 4

The Impact of Pcsk-9 Inhibition on PET CFR in Patients at High CV Risk

Recruiting

NCT04082442Phase 2

Evolocumab in Patients With Acute MI

Completed

NCT05284747Phase 4

EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction